Dr Heather Cunliffe Read more
The presence of a protein called Fn14 on the surface of 75% of invasive breast cancers, has been shown to be strongly prognostic for distant metastasis, with the strongest association in HER2/neu positive and Triple Negative breast cancers.
Dr Anita Dunbier Read more
Treatments that stimulate the immune system to attack tumours have revolutionised the treatment of some cancer types.
Dr Jo Perry Read more
One of the most successful strategies for treating breast cancer has been the use of humanised monoclonal antibodies to target secreted growth factors or cell surface receptors whose function has been upregulated in the tumour.
Associate Professor David Barker Read more
Many patients with metastatic breast cancer do not respond to conventional chemotherapy and better strategies to treat these patients are urgently needed.
Dr Francis Hunter Read more
Over 3000 diagnoses and 600 deaths are attributable to breast cancer in New Zealand each year.
Dr Tracy Hale Read more
Metastasis is the primary cause of death in breast cancer patients as it refractory to current therapies.
Although breast cancer cells have heterogeneous properties, all of them have a high nutritional demand. Read more
Associate Professor Logan Walker Read more
Identification of cancer-causing mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, has well-defined and actionable implications for disease prevention.
Dr Annette Lasham Read more
This translational grant proposes to build on exciting BCRT-funded science that has led to the identification of two RNA markers in the blood, which together may be able to indicate whether a woman has breast cancer or not.
Professor Parry Guilford Read more
The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell.